These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28607567)

  • 1. The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population.
    Abdar M; Ebrahimifar P; Etemadifar M
    ARYA Atheroscler; 2016 Nov; 12(6):274-280. PubMed ID: 28607567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
    Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis.
    Yavari F; Oliazadeh P; Radfar M; Foroughipour M; Nikkhah K; Heidari Bakavoli A; Saeidi M
    Basic Clin Neurosci; 2021; 12(2):233-242. PubMed ID: 34925720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Hughes B; Cascione M; Freedman MS; Agius M; Kantor D; Gudesblatt M; Goldstick LP; Agashivala N; Schofield L; McCague K; Hashmonay R; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):620-8. PubMed ID: 26265274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study.
    Linker RA; Wendt G
    Neurol Ther; 2016 Dec; 5(2):193-201. PubMed ID: 27624575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
    Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal rhythms in patients without known cardiac disease after a first dose of fingolimod.
    Schurmann P; Basra S; Awar OG; Aguilar D; Basant A; Dragan E; Hutton GJ; Birnbaum Y
    Mult Scler Relat Disord; 2014 May; 3(3):408-12. PubMed ID: 25876482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod initiation in multiple sclerosis patients is associated with potential beneficial cardiovascular autonomic effects.
    Hilz MJ; Wang R; de Rojas Leal C; Liu M; Canavese F; Roy S; Hösl KM; Winder K; Lee DH; Linker RA
    Ther Adv Neurol Disord; 2017 Apr; 10(4):191-209. PubMed ID: 28507603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral fingolimod for relapsing-remitting multiple sclerosis Evaluation of: Kappos L, Radue E-M, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401; and Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
    Doggrell SA
    Expert Opin Pharmacother; 2010 Jul; 11(10):1777-81. PubMed ID: 20408749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
    Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
    PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management and outcomes of fingolimod first dose cardiac monitoring in UK patients with relapsing-remitting multiple sclerosis.
    Datt J; Baldock L; Pull E; Webber B
    Mult Scler Relat Disord; 2016 Jan; 5():40-6. PubMed ID: 26856942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
    J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis.
    Li K; Konofalska U; Akgün K; Reimann M; Rüdiger H; Haase R; Ziemssen T
    Front Neurosci; 2017; 11():540. PubMed ID: 29075174
    [No Abstract]   [Full Text] [Related]  

  • 19. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
    Ziemssen T; Kern R; Cornelissen C
    BMC Neurol; 2016 Aug; 16():129. PubMed ID: 27502119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose-Possible Predictors of Cardiac Outcomes.
    Limmroth V; Ziemssen T; Kleiter I; Wagner B; Schmidt S; Lassek C; Baier-Ebert M; Wendt G; Dechend R; Haverkamp W
    Front Neurol; 2020; 11():818. PubMed ID: 32903376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.